Market Cap | 0.90B | P/E | - | EPS this Y | 369.20% | Ern Qtrly Grth | - |
Income | -3.64M | Forward P/E | 50.63 | EPS next Y | 54.30% | 50D Avg Chg | 5.00% |
Sales | 283.18M | PEG | - | EPS past 5Y | - | 200D Avg Chg | 16.00% |
Dividend | N/A | Price/Book | 6.18 | EPS next 5Y | - | 52W High Chg | -6.00% |
Recommedations | 1.70 | Quick Ratio | 1.79 | Shares Outstanding | 231.81M | 52W Low Chg | 106.00% |
Insider Own | 2.84% | ROA | 8.51% | Shares Float | 227.23M | Beta | 0.43 |
Inst Own | 77.83% | ROE | -2.44% | Shares Shorted/Prior | 8.72M/7.29M | Price | 4.05 |
Gross Margin | 40.13% | Profit Margin | -1.29% | Avg. Volume | 2,050,554 | Target Price | 10.50 |
Oper. Margin | 26.65% | Earnings Date | Aug 7 | Volume | 1,241,392 | Change | -2.41% |
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
Raymond James | Strong Buy | May 10, 24 |
Cantor Fitzgerald | Overweight | May 10, 24 |
HC Wainwright & Co. | Buy | May 10, 24 |
Mizuho | Buy | May 10, 24 |
HC Wainwright & Co. | Buy | Mar 26, 24 |
Mizuho | Buy | Mar 1, 24 |
Cantor Fitzgerald | Overweight | Feb 29, 24 |
HC Wainwright & Co. | Buy | Feb 29, 24 |
Mizuho | Buy | Jan 22, 24 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Grossman Jerrold B | Director Director | Aug 30 | Buy | 3.7088 | 130,000 | 482,144 | 443,265 | 08/30/23 |
KWON YOUNG | Director Director | Aug 24 | Buy | 3.9 | 25,000 | 97,500 | 277,401 | 08/24/23 |
Fong Bryant | Director Director | Aug 22 | Sell | 3.8685 | 1,433,304 | 5,544,737 | 08/23/23 | |
Grossman Adam S | President and CEO President and CEO | Aug 18 | Sell | 4.1534 | 250,000 | 1,038,350 | 2,273,085 | 08/18/23 |
Grossman Adam S | President and CEO President and CEO | Aug 15 | Sell | 4.46 | 510,472 | 2,276,705 | 2,523,085 | 08/17/23 |
Grossman Adam S | President and CEO President and CEO | Aug 15 | Option | 2.92 | 2,100,459 | 6,133,340 | 4,623,544 | 08/17/23 |
LENZ BRIAN | EVP, CFO EVP, CFO | Aug 15 | Sell | 4.53 | 389,762 | 1,765,622 | 782,013 | 08/17/23 |
LENZ BRIAN | EVP, CFO EVP, CFO | Aug 15 | Option | 2.92 | 809,262 | 2,363,045 | 1,591,275 | 08/17/23 |
PERCEPTIVE ADVISORS LLC | 10% Owner 10% Owner | Aug 19 | Sell | 1.29 | 1,781,824 | 2,298,553 | 14,802,978 | 08/19/21 |